Sunitinib in patients with cytokine-refiractory metastatic renal cell carcinoma (mRCC)

被引：7
|
作者：
George, D. J. [1 ]
Michaelson, M. D. [2 ]
Rosenberg, J. E. [3 ]
Redman, B. G. [4 ]
Hudes, G. R. [5 ]
Bukowski, R. M. [6 ]
Kim, S. T. [7 ]
Chen, I.
Wilding, G. [8 ]
Motzer, R. J. [9 ]
机构：
[1] Duke Univ, Ctr Med, Durham, NC 27706 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Fox Chase Canc Ctr, Philadelphia, PA USA
[6] Cleveland Clin Taussig Canc Ctr, Cleveland, OH USA
[7] Pfizer Inc, La Jolla, CA USA
[8] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI 53706 USA
[9] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71148-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4517
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [31] Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Roubinov, Keren
    Berger, Raanan
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [32] Side effects of sunitinib malate (SM) treatment for patients (pts) with metastatic renal cell carcinoma (mRCC)
    Carteni, G. G.
    Montano, M.
    Perrotta, E.
    Otero, M.
    Guida, T.
    Ragone, G.
    Aurilio, G.
    Maiorino, L.
    Stavolo, C.
    Panza, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Prognosis of Patients With Metastatic Renal Cell Carcinoma (mRCC) With Primary Resistance to Sunitinib: Is There Any Active Treatment?
    Albiges, L.
    Iacovelli, R.
    Porta, C.
    Houede, N.
    Laguerre, B.
    Procopio, G.
    Lheureux, S.
    Larkin, J.
    Negrier, S.
    Escudier, B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S518 - S518
  • [34] A phase II study of continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) - final results
    Escudier, B.
    Srinivas, S.
    Roigas, J.
    Gillessen, S.
    Harmenberg, U.
    De Mulder, P. H.
    Fountzilas, G.
    Vogelzang, N.
    Peschel, C.
    Flodgren, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 299 - 300
  • [35] SUNITINIB (SU) RECHALLENGE IN METASTATIC RENAL CELL CARCINOMA (MRCC): A SINGLE INSTITUTION EXPERIENCE
    Febbraro, Antonio
    Giordano, Guido
    ANTICANCER RESEARCH, 2014, 34 (05) : 2626 - 2627
  • [36] Long-term response to sunitinib treatment in metastatic renal cell carcinoma (mRCC).
    Tannir, Nizar M.
    Figlin, Robert A.
    Gore, Martin Eric
    Michaelson, Dror
    Motzer, Robert J.
    Porta, Camillo
    Rini, Brian I.
    Hoang, Caroline J.
    Lin, Xun
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [37] Long-term safety with sunitinib (SU) in metastatic renal cell carcinoma (mRCC)
    Porta, C.
    Gore, M. E.
    Rini, B. I.
    Escudier, B.
    Charles, L. P.
    Chen, L.
    Hariharan, S.
    Motzer, R. J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S658 - S658
  • [38] Long-term responders to sunitinib therapy for metastatic renal cell carcinoma (mRCC)
    Molina, A. M.
    Jia, X.
    Ginsberg, M. S.
    Velasco, S.
    Feldman, D. R.
    Patil, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Response of renal lesions in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib - a single center retrospective analysis
    Seidel, C.
    Fenner, M.
    Reuter, C.
    Ivanyi, P.
    Ganser, A.
    Gruenwald, V.
    EJC SUPPLEMENTS, 2009, 7 (02): : 438 - 438
  • [40] Immune cell changes in the peripheral blood of metastatic renal cell carcinoma (mRCC) patients (pts) treated with sunitinib or temsirolimus
    Salas, R. N.
    Ireland, J. L.
    Ko, J. S.
    Elson, P.
    Garcia, J. A.
    Wood, L.
    Bukowski, R. M.
    Rini, B. I.
    Finke, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345